Yazar "Rzazade, Rashad" seçeneğine göre listele

Listeleniyor 1 - 5 / 5
  • Küçük Resim
    Öğe
    Evaluation of interfractional bladder doses for two different patient positioning methods in prostate cancer
    (Elsevier Ireland Ltd., 2015) Altınok, Ayşe; Acar, Hilal; Rzazade, Rashad; Küçük, Nadir; Küçükmorkoç, Esra; Doyuran, Mine; Mabhouti, H.; Çağlar, Hale Başak
    Purpose/Objective: MR imaging following needle implantation in high dose rate brachytherapy (HDR BT) provide more anatomical details for improved definition of the prostate gland, organs at risk, and needles. The purpose of this study was to evaluate the introduction of MRI guided HDR BT, including time consumption, dose volume parameters, and changes over time. Materials and Methods: A team of radiation oncologists, physicists, radiologists, and nurses was trained to perform MRI guided HDR BT. Between September 2012 and November 2014, 42 consecutive high risk prostate cancer patients received two times HDR BT of each 8.5 Gy after EBRT. Time was recorded for initiation of anaesthesia, end of ultrasound guided needle implantation, MR scan, and HDR BT delivery.
  • Küçük Resim Yok
    Öğe
    Investigation of the accuracy of different lung SBRT plans created in eclipse treatment planning system
    (Wiley, 2017) Yıldırım, Sami; Cebe, Mehmet Ata; Mabhouti, H.; Paçacı, P.; Serin, Elise A. R.; Şanlı, Elif; Eşitmez, Dursun; Küçük, Nadir; Doyuran, Mina; Küçükmorkoç, Esra; Çağlar, Mete; Canoğlu, Doğu; Rzazade, Rashad; Acar, Hilal; Özkök, H. Çağlar
    [Abstract Not Available]
  • Küçük Resim Yok
    Öğe
    Investigation of the accuracy of different lung SBRT plans created in multiplan treatment planning system
    (Wiley, 2017) Cebe, Mehmet Ata; Mabhouti, H.; Pacaci, P.; Serin, L.; Şanlı,Elif; Yıldırım, Sami; Eşitmez, Dursun; Küçük, Nadir; Doyuran, Mine; Küçükmorkoç, Esra; Çağlar, Mete; Canoğlu, Doğu; Rzazade, Rashad; Acar, Hilal; Özkök, H. Çağlar
    [Abstract Not Available]
  • Küçük Resim Yok
    Öğe
    Outcomes of patients with oligometastatic non-small cell lung cancer who were treated with radical treatment
    (Elsevier Science Inc, 2017) Bilici, Ahmet; Selçukbiricik, Fatih; Rzazade, Rashad; Ölmez, Ömer Fatih; Çağlar, Hale Başak; Yıldız, Özcan
    [Abstract Not Available]
  • Küçük Resim
    Öğe
    Survival outcomes of patients with oligometastatic non-small cell lung cancer who were treated with radical therapy: A multicenter analysis
    (Turkiye Klinikleri, 2023) Açıkgöz, Özgür; Bilici, Ahmet; Tataroğlu Özyükseler, Deniz; Göktaş Aydin, Sabin; Selçukbiricik, Fatih; Rzazade, Rashad; Ölmez, Ömer Fatih; Başak Çağlar, Hale
    Background/aim: Oligometastatic disease for nonsmall cell lung cancer (NSCLC) patients is generally thought to represent a better prognosis with a quieter biology, limited number of disease sites and long-term disease control. In this study, we aimed to determine the efficacy of radical treatment options for patients with oligometastatic NSCLC. Materials and methods: This retrospective trial included totally 134 patients with oligometastatic NSCLC. The presence of oncodriver mutation, tumor stages and nodal status, the number of metastases and involved metastatic site, treatment of primary tumor and oligometastasis, response rate, overall survival (OS) and progression-free survival (PFS) were evaluated. Results: Of 134 patients 66.4% were defined as adenocarcinoma, 26.1% were squamous cell carcinoma and 7.5% of patients were in other histology. Based on the treatment of primary tumor, in 36 patients (26.9%) curative surgery has undergone, in addition, 19 (14.2%) patients were received chemotherapy, 73 (54.5%) were treated with chemoradiotherapy, while immunotherapy and targeted therapy were used in 1 (0.7%) and 2 (1.4%), respectively. The preferred treatment for oligometastatic lesions were SBRT in 72.4% of patients, surgery in 10.5%, and both SBRT and surgery in 17.1% of patients. At the median follow up of 31.3 months (range: 9.5–48.5), the median PFS and OS times were 17 and 24.4 months, respectively. Moreover, OS-2 after progression was also 7.2 months. Conclusion: Based on our real-life experience, we demonstrated a significant correlation between good response to first treatment and survival in oligometastatic disease, we also understand that local ablative treatment modalities prolong and also delay both OS and PFS in oligometastatic NSCLC patients OS-2.